A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Recruiting

Phase 1

Phase 2

BB-301A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Sponsor:

Benitec Biopharma, Inc.

Code:

NCT06185673

Conditions

Oculopharyngeal Muscular Dystrophy

Eligibility Criteria

Sex: All

Age: 0 - 65

Healthy Volunteers: Not accepted

Interventions

BB-301: Dose escalation phase 1b cohort 1

BB-301: Dose escalation phase 1b cohort 2

BB-301: Dose escalation phase 1b cohort 3

BB-301: Dose expansion phase 2a

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-24. This information was provided to ClinicalTrials.gov by Benitec Biopharma, Inc. on 2025-02-05.